Why measure liver fat?

Excess fat in the liver (steatosis) is the root cause of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), which affect more than 1 billion people globally.

NAFLD and NASH are often asymptomatic. They are reversible when caught early, but can progress to advanced fibrosis, cirrhosis and cancer, which are irreversible. Thus, diagnosing these conditions as soon as possible is key.

NAFLD, NASH and some cases of Fibrosis are reversible.
NAFLD, NASH and some cases of Fibrosis are reversible.
Healthy liver

Healthy liver

Non-Alcoholic Fatty Liver Disease (NAFLD)

Non-Alcoholic Fatty Liver Disease (NAFLD)

Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis (NASH)

Fibrosis

Fibrosis

Cirrhosis or cancer

Cirrhosis or cancer

Until now, options for detection have been limited.

Invasive liver biopsy and expensive MRI have been the only options, meaning detection and monitoring for most patients is out of the question.

ENDRA is focused on early detection of liver disease.

TAEUS® is a new, proprietary way to measure fat in the liver that is now CE-marked for sale in Europe. The technology is non-invasive and costs 50x less than MRI.

CE certified
TAEUS® liver is CE-marked for sale in Europe, but not yet FDA approved for sale in the US.
TAEUS probe
TAEUS® works with any B-mode ultrasound machine, but it does what ultrasound alone cannot do: Measure steatosis (liver fat) and early staging of NAFLD/NASH.

TAEUS® works with any B-mode ultrasound machine, but it does what ultrasound alone cannot do: Measure steatosis (liver fat) and early staging of NAFLD/NASH.

TAEUS® uses a unique, groundbreaking combination of radio frequency and ultrasound to characterize human tissue in a way similar to MRI—at 50x lower cost, and at the point of patient care.

With TAEUS®, clinicians can measure steatosis (liver fat) in less than a minute.

When the first targeted therapies for NAFLD and NASH hit the market in 2020–2021, will your clinical practice be ready to assess and monitor it quickly and easily?

Endra Explained

“If we could diagnose NAFLD-NASH early in the disease cycle, while it is still reversible, with a tool that is safe and easily accessible at the point of patient care, it could improve the health of millions of people and dramatically lower healthcare costs associated with later-stage acute disease management. ENDRA’s Thermo Acoustic Enhanced Ultrasound® (TAEUS®) liver device could be a game changer in the clinical care cycle of liver disease.”

— Sam Gambhir, M.D, Ph.D

Chair, Dept. of Radiology and Director, Molecular Imaging Program, Stanford University
Watch the video

What is TAEUS®?

Thermo-Acoustic Enhanced UltraSound will revolutionize what doctors can see and do at the patient bedside.

WATCH THE VIDEO >
Watch the video

Meet Mary

Learn how ENDRA is using ultrasound to help make difficult-to-diagnose diseases easier to find and treat.

WATCH THE VIDEO >
Watch the video

TAEUS® for clinicians

See how TAEUS® is making it easier and more cost-effective than ever to assess and monitor fat in the liver.

WATCH THE VIDEO >

We’re only at the beginning of what’s possible.

TAEUS® will close gaps in a variety of other applications, such as visualizing tissue temperature during energy-based surgery and identifying arterial plaque or internal bleeding.

See more. Do more. Live better.

GET IN TOUCH WITH ENDRA >